Diacylglycerol O-acyltransferase 2 (DGAT2) inhibitors are promising ones aimed at the treatment of metabolic disorders, particularly non-alcoholic steatohepatitis, type 2 diabetes, and hyperlipidemia. The gene discussed is DGAT2; the disease is metabolic disease.